iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

Inclusion Criteria: * Males and females \> 50 years of age with a diagnosis of PED secondary to AMD or PCV * Serous and/or fibrovascular PED secondary to exudative AMD or secondary to PCV (confirmed by SDOCT, FA and ICG) that has not demonstrated at least a 25% decrease in the height of the PED (from the onset of anti-VEGF therapy) following a minimum of 3 doses of an anti-VEGF agent (i.e., Lucentis or Avastin) * PED that has a height greater than 100 μm * Presence of CNV secondary to (i) AMD (based on FA) or (ii) PCV (based on ICG) * ETDRS BCVA of 20/32 to 20/320 (letter score of 73 to 25) in the study eye * ETDRS visual acuity of 20/400 or better in the fellow eye Exclusion Criteria: * Subjects previously treated with, or are currently receiving treatment with another investigational agent or device for neovascular AMD in the study eye * Subjects who have received \< 3 and \> 7 anti-VEGF treatments in the study eye * Subjects with retinal angiomatous proliferation (RAP lesion) * Lucentis or Avastin within 30 days prior to Day 1 in the study eye